drugset / Trial / NCT01966809

Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas

NCT01966809

NaSingle-groupOpen-labelTreatment

Summary

This study will be aimed at investigating the effectiveness of a treatment for brain tumors called Photodynamic Therapy, or PDT. Briefly, a subject will receive a light-sensitive drug, called Photofrin®, the day before a tumor removal surgery. The next day, after the tumor is removed, red light from a laser will be shone into the tumor cavity through a light-diffusing sphere. This light will activate the photosensitizer, and possibly kill any tumor cells that may be left. We plan to measure how long the subject may go without a new tumor regrowth, and overall how long subjects survive. We will compare these results to typical results to see if we are seeing any improvements. Objective: To define the antitumor activity of Photofrin® and laser light activation within the confines of a Phase II study.

Timeline

Start
2015-06
Primary completion
2017-12-19
Completion
2017-12-19

Drugs

EvaluationDrugModalityDoseRoute
Subject porfimer sodium Small molecule 2.5 mg/kg Intravenous

Indications